New Kidney Drug Cuts Death Risk in Two-Year Trial

Vera Therapeutics' newly approved kidney drug Trutakna has delivered strong two-year results that could help thousands of people fighting a chronic autoimmune disease avoid dialysis and organ failure.

The company is now seeking full FDA approval based on the promising data.